Community post
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 23, 2024
A New Study Exploring CAR T After Transplant
AI-generated title
A research study is being performed with the goal of improving outcomes for newly diagnosed multiple myeloma patients whose myeloma hasn’t responded optimally to traditional induction and stem cell transplant therapy.  Lenalidomide is traditionally used as a maintenance therapy to deepen responses after transplant, but this study aims to test whether adding CAR T therapy can further improve responses and outcomes.  Learn more about this study at: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06045806?cid=s_2839286 Funded by Bristol Myers Squibb.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | BMS Clinical Trials

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | BMS Clinical Trials

Explore Potential treatments for adults with newly diagnosed Multiple Myeloma who didn't respond well after a stem cell transplant. See if you qualify and learn how to join a Clinical Study at Bristol Myers Squibb

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06045806?cid=s_2839286
Avatar

No comments yet.

Related Content